Stemline - Model SL-701 - Immunotherapy
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. A multicenter Phase 2 trial of SL-701 in adult patients with second-line glioblastoma multiforme (GBM) has been completed, and data suggest that SL-701 is generating a target-specific CD8+ T-cell response, which may be translating into improved clinical outcomes, including improved overall survival, in a subset of patients. Given the safety and efficacy data generated to date with SL-701 and bevacizumab in second-line GBM, an indication of unmet need, we are considering next steps including leveraging these results and the potential immune-related data in registration-directed trial designs.
-
Most popular related searches
SL-701 Background and Mechanism of Action
SL-701 is an off-the-shelf, systemically delivered (subcutaneous) immunotherapy designed to target IL-13R?2, EphA2, and survivin, which overexpressed on glioblastoma (GBM). Composed of short, synthetic peptides, some mutated, SL-701 appears to generate an antigen-specific CD8+ T-cell response when coadministered with immunostimulants.
Customer reviews
No reviews were found for Stemline - Model SL-701 - Immunotherapy. Be the first to review!